Effects of cigarette smoking and nicotine metabolite ratio on leukocyte telomere length.

Environmental Research

Volumn 140, Issue , 2015, Pages 488-494

  Verde, Zoraida ^a   Reinoso Barbero, Luis ^a,b   Chicharro, Luis ^a   Garatachea, Nuria ^c   Resano, Pilar ^d   Sánchez Hernández, Ignacio ^e   Rodríguez González Moro, Jose Miguel ^f   Bandrés, Fernando ^g   Santiago, Catalina ^a   Gómez Gallego, Félix ^a  

^a UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^b Grupo Banco Popular   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d Guadalajara Hospital   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

3 OH cotinine; Cotinine; CYP2A6; Leukocyte telomere length; Nicotine; NMR; Pack years smoked

Indexed keywords

3' HYDROXYCOTININE; COTININE; CYTOCHROME P450 2A6; NICOTINE; NITROSAMINE; BIOLOGICAL MARKER; CYP2A6 PROTEIN, HUMAN;

ALKALOID; BLOOD; CHEMICAL ANALYSIS; CHROMOSOME; GENOTYPE; INJURY; METABOLITE; SMOKING; TOXIN; URINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELLULAR PARAMETERS; DRUG URINE LEVEL; EXPOSURE; FEMALE; HUMAN; LEUKOCYTE; LEUKOCYTE TELOMERE LENGTH; MALE; METABOLIC PARAMETERS; METABOLITE; NICOTINE METABOLISM RATIO; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; TELOMERE; TOBACCO CONSUMPTION; URINALYSIS; GENETICS; METABOLISM; TOBACCO; ULTRASTRUCTURE; URINE;

NEPTUNIA; NICOTIANA TABACUM;

BIOLOGICAL MARKERS; CYTOCHROME P-450 CYP2A6; HUMANS; LEUKOCYTES; NICOTINE; SMOKING; TELOMERE; TOBACCO;

EID: 84930943830     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2015.05.008     Document Type: Article

References (72)

1. Ahotupa M., Bussacchini-Griot V., Bereziat J.C., Camus A.M., Bartsch H. Rapid oxidative stress induced by N-nitrosamines. Biochem. Biophys. Res. Commun. 1987, 146(3):1047-1054.
2. Alberg A.J., Shopland D.R., Cummings K.M. The 2014 surgeon general's report: commemorating the 50th anniversary of the 1964 report of the advisory committee to the US surgeon general and updating the evidence on the health consequences of cigarette smoking. Am. J. Epidemiol. 2014, 179(4):403-412.
3. Aviv A., Susser E. Leukocyte telomere length and the father's age enigma: implications for population health and for life course. Int. J. Epidemiol. 2013, 42(2):457-462.
4. Benowitz N.L. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol. Rev. 1996, 18(2):188-204.
5. Benowitz N.L. Nicotine addiction. N. Engl. J. Med. 2010, 362(24):2295-2303.
6. Benowitz N.L., Pomerleau O.F., Pomerleau C.S., Jacob P. . Nicotine metabolite ratio as a predictor of cigarette consumption. Nicot. Tob. Res.: Off. J. Soc. Res. Nicot. Tob. 2003, 5(5):621-624.
7. Benowitz N.L., Schultz K.E., Haller C.A., Wu A.H., Dains K.M., Jacob P. Prevalence of smoking assessed biochemically in an urban public hospital: a rationale for routine cotinine screening. Am. J. Epidemiol. 2009, 170(7):885-891.
8. Boffetta P., Clark S., Shen M., Gislefoss R., Peto R., Andersen A. Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol. Biomark. Prev. 2006, 15(6):1184-1188.
9. Broberg K., Bjork J., Paulsson K., Hoglund M., Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 2005, 26(7):1263-1271.
10. Cawthon R.M. Telomere measurement by quantitative PCR. Nucl. Acids Res. 2002, 30(10):e47.
11. Chen S., Yeh F., Lin J., Matsuguchi T., Blackburn E., Lee E.T., et al. Short leukocyte telomere length is associated with obesity in american indians: the strong heart family study. Aging 2014, 6(5):380-389.
12. Cherkas L.F., Hunkin J.L., Kato B.S., Richards J.B., Gardner J.P., Surdulescu G.L., et al. The association between physical activity in leisure time and leukocyte telomere length. Arch. Intern. Med. 2008, 168(2):154-158.
13. Clague J., Shao L., Lin J., Chang S., Zhu Y., Wang W., et al. Sensitivity to NNKOAc is associated with renal cancer risk. Carcinogenesis 2009, 30(4):706-710.
14. Codd V., Mangino M., van der Harst P., Braund P.S., Kaiser M., Beveridge A.J., et al. Common variants near TERC are associated with mean telomere length. Nat. Genet. 2010, 42(3):197-199.
15. Dempsey D., Tutka P., Jacob P.,3rd, Allen F., Schoedel K., Tyndale R.F., et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 2004, 76(1):64-72.
16. Derby K.S., Cuthrell K., Caberto C., Carmella S.G., Franke A.A., Hecht S.S., et al. Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol. Biomark. Prev. 2008, 17(12):3526-3535.
17. Djordjevic M.V., Stellman S.D., Zang E. Doses of nicotine and lung carcinogens delivered to cigarette smokers. J. Natl. Cancer Inst. 2000, 92(2):106-111.
18. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11(1):81-128.
19. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345(6274):458-460.
20. Hecht S.S. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol. 2002, 3(8):461-469.
21. Ho M.K., Faseru B., Choi W.S., Nollen N.L., Mayo M.S., Thomas J.L., et al. Utility and relationships of biomarkers of smoking in African-American light smokers. Cancer Epidemiol. Biomark. Prev. 2009, 18(12):3426-3434.
22. Houben J.M., Moonen H.J., van Schooten F.J., Hageman G.J. Telomere length assessment: Biomarker of chronic oxidative stress?. Free Radic. Biol. Med. 2008, 44(3):235-246.
23. Hukkanen J., Jacob P.,3rd, Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 2005, 57(1):79-115.
24. Hukkanen J., Jacob P.,3rd, Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 2005, 57(1):79-115.
25. Huzen J., Wong L.S., van Veldhuisen D.J., Samani N.J., Zwinderman A.H., Codd V., et al. Telomere length loss due to smoking and metabolic traits. J. Intern. Med. 2014, 275(2):155-163.
26. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans,2004. Tobacco smoke and involuntary smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans/World Health Organization, International Agency for Research on Cancer, vol. 83, p. 1-1438.
27. Johnstone E., Benowitz N., Cargill A., Jacob R., Hinks L., Day I., et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin. Pharmacol.Ther. 2006, 80(4):319-330.
28. Joseph A.M., Hecht S.S., Murphy S.E., Carmella S.G., Le C.T., Zhang Y., et al. Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol. Biomark. Prev. 2005, 14(12):2963-2968.
29. Joseph A.M., McFall M., Saxon A.J., Chow B.K., Leskela J., Dieperink M.E., et al. Smoking intensity and severity of specific symptom clusters in posttraumatic stress disorder. J. Trauma. Stress 2012, 25(1):10-16.
30. Joseph A.M., Muggli M., Pearson K.C., Lando H. The cigarette manufacturers' efforts to promote tobacco to the U.S. military. Mil. Med. 2005, 170(10):874-880.
31. Kannel W.B. Update on the role of cigarette smoking in coronary artery disease. Am. Heart J. 1981, 101(3):319-328.
32. Lan Q., Cawthon R., Gao Y., Hu W., Hosgood H.D.,3rd, Barone-Adesi F., et al. Longer telomere length in peripheral white blood cells is associated with risk of lung cancer and the rs2736100 (CLPTM1l-TERT) polymorphism in a prospective cohort study among women in china. PloS One, 2013, 8(3):e59230.
33. Lea R.A., Dickson S., Benowitz N.L. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J. Anal. Toxicol. 2006, 30(6):386-389.
34. Leffondre K., Abrahamowicz M., Siemiatycki J., Rachet B. Modeling smoking history: a comparison of different approaches. Am. J. Epidemiol. 2002, 156(9):813-823.
35. Lerman C.E., Schnoll R.A., Munafo M.R. Genetics and smoking cessation improving outcomes in smokers at risk. Am. J. Prev. Med. 2007, 33(Suppl. 6):S398-405.
36. Lessov-Schlaggar C.N., Pergadia M.L., Khroyan T.V., Swan G.E. Genetics of nicotine dependence and pharmacotherapy. Biochem. Pharmacol. 2008, 75(1):178-195.
37. Li H., Jonsson B.A., Lindh C.H., Albin M., Broberg K. N-nitrosamines are associated with shorter telomere length. Scand. J. Work Environ. Health 2011, 37(4):316-324.
38. London S.J., Idle J.R., Daly A.K., Coetzee G.A. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999, 353(9156):898-899.
39. Malaiyandi V., Goodz S.D., Sellers E.M., Tyndale R.F. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol. Biomark. Prev. 2006, 15(10):1812-1819.
40. Martinez-Delgado B., Yanowsky K., Inglada-Perez L., Domingo S., Urioste M., Osorio A., et al. Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS Genet. 2011, 7(7):e1002182.
41. Martin-Ruiz C.M., Gussekloo J., van Heemst D., von Zglinicki T., Westendorp R.G. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell 2005, 4(6):287-290.
42. Messina E.S., Tyndale R.F., Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 1997, 282(3):1608-1614.
43. Molander L., Hansson A., Lunell E. Pharmacokinetics of nicotine in healthy elderly people. Clin.l Pharmacol. Ther. 2001, 69(1):57-65.
44. Morla M., Busquets X., Pons J., Sauleda J., MacNee W., Agusti A.G. Telomere shortening in smokers with and without COPD. Eur. Respir. J. 2006, 27(3):525-528.
45. NCI-NHGRI Working Group on Replication in Association Studies, Chanock S.J., Manolio T., Boehnke M., Boerwinkle E., Hunter D.J., et al. Replicating genotype-phenotype associations. Nature 2007, 447(7145):655-660.
46. Oddoze C., Dubus J.C., Badier M., Thirion X., Pauli A.M., Pastor J., et al. Urinary cotinine and exposure to parental smoking in a population of children with asthma. Clin. Chem. 1999, 45(4):505-509.
47. Pomerleau O.F. Individual differences in sensitivity to nicotine: Implications for genetic research on nicotine dependence. Behav. Genet. 1995, 25(2):161-177.
48. Rode L., Bojesen S.E., Weischer M., Nordestgaard B.G. High tobacco consumption is causally associated with increased all-cause mortality in a general population sample of 55,568 individuals, but not with short telomeres: a mendelian randomization study. Int. J. Epidemiol. 2014, 43(5):1473-1483.
49. Rubinstein M.L., Benowitz N.L., Auerback G.M., Moscicki A.B. Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. Pediatrics 2008, 122(3):e643-7.
50. Rufer N., Brummendorf T.H., Kolvraa S., Bischoff C., Christensen K., Wadsworth L., et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J. Exp. Med. 1999, 190(2):157-167.
51. Samani N.J., Boultby R., Butler R., Thompson J.R., Goodall A.H. Telomere shortening in atherosclerosis. Lancet 2001, 358(9280):472-473.
52. Savale L., Chaouat A., Bastuji-Garin S., Marcos E., Boyer L., Maitre B., et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009, 179(7):566-571.
53. Schnoll R.A., Patterson F., Wileyto E.P., Tyndale R.F., Benowitz N., Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol. Biochem. Behav. 2009, 92(1):6-11.
54. St Helen G., Dempsey D., Wilson M., Jacob P., Benowitz N.L. Racial differences in the relationship between tobacco dependence and nicotine and carcinogen exposure. Addiction 2013, 108(3):607-617.
55. Strasser A.A., Benowitz N.L., Pinto A.G., Tang K.Z., Hecht S.S., Carmella S.G., et al. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol. Biomark. Prev. 2011, 20(2):234-238.
56. Strasser A.A., Malaiyandi V., Hoffmann E., Tyndale R.F., Lerman C. An association of CYP2A6 genotype and smoking topography. Nicot. Tob. Res.: Off. J. Soc. Res. Nicot. Tob. 2007, 9(4):511-518.
57. Strasser A.A., O'Connor R.J., Mooney M.E., Wileyto E.P. Digital image analysis of cigarette filter stains as an indicator of compensatory smoking. Cancer Epidemiol. Biomark. Prev. 2006, 15(12):2565-2569.
58. Tyndale R.F., Sellers E.M. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab. Dispos.: Biol. Fate Chem. 2001, 29(4 Pt2):548-552.
59. Valdes A.M., Andrew T., Gardner J.P., Kimura M., Oelsner E., Cherkas L.F., et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005, 366(9486):662-664.
60. Verde Z., Santiago C., Rodriguez Gonzalez-Moro J.M., de Lucas Ramos P., Lopez Martin S., Bandres F., et al. Smoking genes: a genetic association stu. PloS One 2011, 6(10):e26668.
61. Verde Z., Santiago C., Rodriguez Gonzalez-Moro J.M., de Lucas Ramos P., Lopez Martin S., Bandres F., et al. Are serotonergic system genes associated to smoking cessation therapy success in addition to CYP2A6?. Pharmacopsychiatry 2014, 47(1):33-36.
62. von Zglinicki T., Saretzki G., Docke W., Lotze C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence?. Exp. Cell Res. 1995, 220(1):186-193.
63. Voulgaridou G.P., Anestopoulos I., Franco R., Panayiotidis M.I., Pappa A. DNA damage induced by endogenous aldehydes: current state of knowledge. Mutat. Res. 2011, 711(1-2):13-27.
64. Walters M.S., De B.P., Salit J., Buro-Auriemma L.J., Wilson T., Rogalski A.M., et al. Smoking accelerates aging of the small airway epithelium. Respir.Res. 2014, 15(1). 94-014-0094-1.
65. Weischer M., Bojesen S.E., Nordestgaard B.G. Telomere shortening unrelated to smoking, body weight, physical activity, and alcohol intake: 4576 general population individuals with repeat measurements 10 years apart. PLoS Genet. 2014, 10(3):e1004191.
66. Willeit P., Willeit J., Mayr A., Weger S., Oberhollenzer F., Brandstatter A., et al. Telomere length and risk of incident cancer and cancer mortality. J. Am. Med. Asso. 2010, 304(1):69-75.
67. Willers S., Axmon A., Feyerabend C., Nielsen J., Skarping G., Skerfving S. Assessment of environmental tobacco smoke exposure in children with asthmatic symptoms by questionnaire and cotinine concentrations in plasma, saliva, and urine. J. Clin. Epidemiol. 2000, 53(7):715-721.
68. Wolkowitz O.M., Mellon S.H., Epel E.S., Lin J., Dhabhar F.S., Su Y., et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress - preliminary findings. PloS One 2011, 6(3):e17837.
69. Wu X., Amos C.I., Zhu Y., Zhao H., Grossman B.H., Shay J.W., et al. Telomere dysfunction: a potential cancer predisposition factor. J. Natl. Cancer Inst. 2003, 95(16):1211-1218.
70. Zakian V.A. Telomeres: beginning to understand the end. Science 1995, 270(5242):1601-1607.
71. Zhu A.Z., Renner C.C., Hatsukami D.K., Swan G.E., Lerman C., Benowitz N.L., et al. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol. Biomark. Prev. 2013, 22(4):708-718.
72. Zhu A.Z., Zhou Q., Cox L.S., Ahluwalia J.S., Benowitz N.L., Tyndale R.F. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. PloS One, 2013, 8(8):e70938.